Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
AssigneeMolecular Insight Pharmaceuticals, Inc.
InventorsJohn W. Babich, Shawn Hillier, John Joyal
Life of this patent
Estimating the term…
Abstract
A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.
Claims17
A therapeutic radionuclide regimen for treating cancerous prostate tissue in a subject, the regimen comprising administering an agent to the subject and after allowing a waiting period of 1 hour to 60 hours to pass administering a compound comprising a recognition moiety for Prostate Specific Membrane Antigen (“PSMA”) and a radionuclide to a subject harboring the cancerous prostate tissue;
- wherein:
- the compound binds to both cancerous prostate tissue and non-cancerous tissue;
- the compound is administered in an amount sufficient to cause a displacement of the agent in cancerous tissue;
- the agent does not include a radionuclide;
- the compound is a Glu-urea-based PSMA ligand;
- and
- the agent comprises a Glu-urea-based PSMA ligand, a phosphinyl containing moiety, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamide)-2-heptenoic acid, 2-(phosphonomethyl)pentanedioic acid, or 2-(3-mercaptopropyl)pentanedioic acid (2-MPPA).
A treatment protocol for a subject diagnosed with cancer, the protocol comprising:
- a) administering an agent to the subject;
- b) after allowing a waiting period of 1 hour to 60 hours to pass;
- and then
- c) administering a compound comprising a recognition moiety for Prostate Specific Membrane Antigen (“PSMA”) and a radionuclide to the subject;
- wherein:
- the compound binds to both cancerous prostate tissue and non-cancerous tissue;
- the compound is administered in an amount sufficient to cause a displacement of the agent in cancerous tissue;
- the agent does not include a radionuclide;
- the compound is a Glu-urea-based PSMA ligand;
- and
- the agent comprises a Glu-urea-based PSMA ligand, a phosphinyl containing moiety, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethyl cyclopropanecarboxamide)-2-heptenoic acid, 2-(phosphonomethyl)pentanedioic acid, or 2-(3-mercaptopropyl)pentanedioic acid (2-MPPA).
Dependencies are inferred from the claim text.